



## LJMU Research Online

**Uddin, SJ, Afroz, M, Zihad, SMNK, Rahman, MS, Akhter, S, Khan, IN, Al-Rabbi, SMS, Rouf, R, Islam, MT, Shilpi, JA, Nahar, L, Tirlongo, E and Sarker, SD**

**A systematic review on anti-diabetic and cardioprotective effects of gallic acid: A widespread dietary phytoconstituent**

<http://researchonline.ljmu.ac.uk/id/eprint/12486/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Uddin, SJ, Afroz, M, Zihad, SMNK, Rahman, MS, Akhter, S, Khan, IN, Al-Rabbi, SMS, Rouf, R, Islam, MT, Shilpi, JA, Nahar, L, Tirlongo, E and Sarker, SD (2020) A systematic review on anti-diabetic and cardioprotective effects of gallic acid: A widespread dietary phytoconstituent. Food Reviews**

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>

1           **A Systematic Review on Anti-diabetic and Cardioprotective Potential of**  
2                           **Gallic Acid: A Widespread Dietary Phytoconstituent**

3  
4   Shaikh Jamal Uddin<sup>1,2,\*</sup>, Mohasana Afroz<sup>3</sup>, S. M. Neamul Kabir Zihad<sup>3</sup>, Md. Shamim Rahman<sup>4</sup>,  
5   Sanzida Akter<sup>3</sup>, Ishaq N. Khan<sup>5</sup>, S. M. Sabik Al-Rabbi<sup>3</sup>, Razina Rouf<sup>6</sup>, Muhammad Torequl  
6   Islam<sup>6</sup>, Jamil A. Shilpi<sup>3</sup>, Lutfun Nahar<sup>7</sup>, Evelin Tiralongo<sup>8</sup>, Satyajit D. Sarker<sup>7</sup>

7  
8  
9   <sup>1</sup>*Department for Management of Science and Technology Development, Ton Duc Thang*  
10 *University, Ho Chi Minh City-700000, Vietnam*

11   <sup>2</sup>*Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City-700000, Vietnam*

12   <sup>3</sup>*Pharmacy Discipline, Life Science School, Khulna University, Khulna 9208, Bangladesh*

13   <sup>4</sup>*Biotechnology and Genetic Engineering Discipline, Life Science School, Khulna University,*  
14 *Khulna 9208, Bangladesh*

15   <sup>5</sup>*PK-NeuroOncology Research Group, Institute of Basic Medical Sciences, Khyber Medical*  
16 *University, Peshawar, 25000, Pakistan*

17   <sup>6</sup>*Department of Pharmacy, Faculty of Life Science, Bangabandhu Sheikh Mujibur Rahman*  
18 *Science & Technology University, Gopalganj, Bangladesh*

19   <sup>7</sup>*Medicinal Chemistry and Natural Products Research Group, School of Pharmacy and*  
20 *Biomolecular Sciences, Liverpool John Moores University, Liverpool, United Kingdom*

21   <sup>8</sup>*School of Pharmacy and Menzies Health Institute QLD, Griffith University, Southport, Qld,*  
22 *Australia*

23  
24  
25  
26  
27   **\*Correspondence:**

28   **Dr. Shaikh Jamal Uddin**

29   Department for Management of Science and Technology Development & Faculty of Pharmacy,  
30   Ton Duc Thang University, Ho Chi Minh City-700000, Vietnam

31   E-mail: [shaikh.jamal.uddin@tdtu.edu.vn](mailto:shaikh.jamal.uddin@tdtu.edu.vn)

1 **ABSTRACT**

2 Gallic acid (GA) is a bioactive phytoconstituent that has been reported to prevent a number of  
3 diseases. However, there is no systematic review to-date on its anti-diabetic and cardioprotective  
4 potential including molecular mechanisms for such activities. This review aims to summarize the  
5 anti-diabetic and cardioprotective effects of gallic acid and further propose a molecular  
6 mechanism of its anti-diabetic effects. Accumulation of associated literature was conducted  
7 through the use of databases including Google Scholar, Pubmed, Web of Science, Science Direct  
8 and Scopus databases. Articles published until December 2018 were extracted and all the  
9 retracted articles were sorted based on the inclusion and exclusion criteria and relevant articles  
10 were further consulted for necessary information. We have found substantial investigations in  
11 animals and cultured cells that supports anti-diabetic and cardioprotective effects of GA with  
12 several underlying mechanisms including antioxidant enzyme systems and non-enzymatic  
13 defense mechanisms. The reported antioxidant activity of GA as well as the modulation of some  
14 key proteins linked to diabetes could be a part of the mechanisms by which GA showed anti-  
15 diabetic effect. In summary, it is evident that GA is one of the promising dietary phytochemicals  
16 that could be beneficial for the treatment and management of diabetes and associated myocardial  
17 damage.

18 **Key words:** Gallic acid, anti-diabetic, cardioprotective, antioxidant; dietary phytoconstituents

19

20

21

22

23

24

25

26

1 **List of abbreviation:**

2 AGEs, Advanced glycation end products; Akt, Protein Kinase B; ALT, Alanine transaminase;  
3 AMPK $\alpha$ , AMP-activated protein kinase- alpha; AMPK $\gamma$ , AMP-activated protein kinase-gamma;  
4 ANP, Atrial natriuretic peptide; AST, Aspartate transaminase; b.w, Body weight; CAT, Catalase;  
5 CK, Creatine kinase; CK-MB, Creatine kinase-myoglobin binding; CPK, Creatine  
6 phosphokinase; CRP, C-reactive protein; CsA, Cyclosporine A; CVDs, Cardiovascular diseases;  
7 Cx43, Gap junction protein Connexin 43; CYP, Cyclophosphamide; CTGF, Connective tissue  
8 growth factor; DM, Diabetes mellitus; D-MI, Diabetes with myocardial infraction; DOX,  
9 Doxorubicin; ECM, Extracellular matrix; ERKs, Extracellular signal-regulated kinases; GA,  
10 Gallic acid; GSIS, Glucose-stimulated insulin secretion; GLUT4, Glucose transporter protein 4;  
11 GLUT2, Glucose transporter protein 2; GR, Glutathione reductase; GSH, Reduced Glutathione  
12 reductase; GST, Glutathione-S-transferase; GATA4, Transcription factor GATA-4; HDL, High  
13 density lipoprotein; H9c2(2-1), Embryonic rat cardiomyocyte cell line; iNOS, Inducible nitric  
14 oxide synthase; ISO, Isoproterenol ; JNKs, c-Jun N-terminal kinases; L-NAME, N-nitro-L-  
15 arginine methyl ester; LDL-C, LDL-cholesterol; LDH, Lactate dehydrogenase; LDL, Low  
16 density lipoprotein; LOOH , Lipid hydroperoxides; LPO, Lipid peroxidation; LV, Left  
17 ventricular; MDA, Malondialdehyde; MHC- $\beta$ , Myosin heavy chain beta; MI, Myocardial  
18 infraction; MMP, Matrix metalloproteinase; Na<sup>+</sup>/K<sup>+</sup>-ATPase, Sodium-  
19 potassium adenosine triphosphatase; Nox2, NADPH oxidase 2; PCO, Protein carbonyls; PGC1 $\alpha$ ,  
20 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PI, Plasma insulin;  
21 PI3K, Phosphatidylinositol 3-kinase; PPAR $\gamma$ , Peroxisome proliferator-activated receptors-  
22 gamma; RAGE, Receptor for AGE; ROS, Reactive oxygen species; SC, Serum creatinine; SOD,  
23 Superoxide dismutase ; GPx, Glutathione peroxidase; SHR, Spontaneously hypertensive rats;  
24 STZ, Streptozotocin; TBARS, Thiobarbituric acid reactive substances; TC, Total cholesterol; TG,  
25 Triglyceride; TGF- $\beta$ , Transforming growth factor beta; TIMP, Tissue inhibitor of  
26 metalloproteinases; TNF- $\alpha$ , Tumor necrosis factor-alpha; TnI, Troponin-I;  
27 TZDs, Thiazolidinediones; UA, Uric acid ; UCP2, Uncoupling protein 2; XO, Xanthine oxidase

28

29

## 1 **Introduction**

2 Diabetes mellitus (DM) and cardiovascular diseases (CVDs) are the two most common causes of  
3 deaths that are spreading spontaneously around the world.<sup>[1, 2]</sup> Approximately 347 million people  
4 around the world are suffering from DM<sup>[3]</sup> and it is projected that about 592 million people  
5 worldwide will have DM by 2035.<sup>[4]</sup> In diabetes, glucose utilization is reduced as a results of  
6 compromised insulin secretion.<sup>[5]</sup> DM causes different ailments including neuropathy, micro and  
7 macro vascular diseases as well as nephropathy through inhibiting body's antioxidant  
8 mechanisms.<sup>[6]</sup> A number of reports confirmed that the link between DM and CVDs was the  
9 most predominant cause of morbidity and mortality in diabetic patients.<sup>[4]</sup> According to various  
10 studies, hyperglycemia is a prime cause of CVDs in DM patients.<sup>[7]</sup> Excessive blood glucose in  
11 DM patients can react with amino acid residues of proteins as well as free amino acids to form  
12 advanced glycation end products (AGEs) by non-enzymatic glycosylation reaction and this plays  
13 an important role in the pathogenesis of diabetic complications including cardiomyopathy.<sup>[8]</sup> The  
14 high levels of circulating and myocardial AGEs remains elevated <sup>[9]</sup> in DM which also  
15 contributes to heart failure.<sup>[10]</sup> Diabetes increases atherosclerotic progression and adversely  
16 contributes to the lipid profile resulting in the increased risk of myocardial infraction (MI) .<sup>[11]</sup> A  
17 number of molecules are currently exists to control DM and CVDs with varying degrees of  
18 success, but there is still no magic molecule that can control DM and its associated CVDs  
19 simultaneously.

20 Gallic acid (GA), chemically known as 3,4,5-trihydroxybenzoic acid, is a naturally  
21 occurring aromatic polyphenolic acid mostly found in different fruits and other plants.<sup>[12]</sup> GA  
22 mainly occurs in plants in the form of free acids or as esters in catechin derivatives and  
23 hydrolysable tannins (Fig. 1). Different fruits and foodstuffs contain different amounts of GA

1 including strawberries, bananas, grapes<sup>[13, 14]</sup>, teas<sup>[15]</sup>, cloves<sup>[16]</sup>, and vinegars<sup>[17]</sup>. GA has been  
2 reported to occur in a number of terrestrial plants such as *Cynomorium coccineum*, *Garcinia*  
3 *densivenia*, *Bridelia micrantha*, *Diospyros cinnabarina*, *Terminalia bellerica*<sup>[18, 19]</sup>, as well as in  
4 aquatic plant *Myriophyllum spicatum*, and the blue-green algae *Microcystis aeruginosa*.<sup>[20]</sup>  
5 Various oak species<sup>[21]</sup>, stem bark of *Boswellia dalzielii*<sup>[22]</sup>, and *Caesalpinia mimosoides*<sup>[23]</sup>, also  
6 contain GA. GA has been reported to be used as a dietary herbal supplement<sup>[24]</sup> and about thirty  
7 ayurvedic formulations containing considerable amount of GA are used for different diseases in  
8 India.<sup>[25]</sup> GA is a strong natural antioxidant and has the ability to combat different reactive  
9 oxygen species (ROS).<sup>[26]</sup> GA is reported to affect multiple pharmacological and biochemical  
10 pathways through which it exerts a number of biological activities including anti-inflammatory,  
11 anti-diabetic, cardioprotective, anti-cancer and hepatoprotective activity (Table 1). However,  
12 there is no systematic review to-date covering its anti-diabetic and cardioprotective effects. The  
13 aim of this review is to summarize the anti-diabetic and cardioprotective effects of GA with  
14 focus on underlying mechanisms of action that is available in published literature using afore-  
15 mentioned databases.

## 16 **Search strategy**

17 A comprehensive literature search was conducted by using several databases including PubMed,  
18 Google Scholar, Web of Science, Science Direct and Scopus with the term ‘gallic acid’ with  
19 ‘anti-diabetic’, ‘diabetes’, ‘cardioprotective’, ‘cardiovascular disease’ ‘myocardial damage’ and  
20 ‘cardiotoxicity’. Reports that are only in English were selected due to the language barrier, time  
21 efficiency and non-feasible costs of translation.

## 22 **Selection of studies for inclusion in the systematic review**

1 To prepare this review, a number of criteria have been structured to include articles in this  
2 review. The following types of reports were included in this review: a) *in vivo* animal studies, b)  
3 *in vitro* studies, c) studies that include the effects of GA on diabetes and cardiovascular diseases,  
4 e) studies that indicate the concentrations or doses employed and the form of administration and  
5 f) studies that pointed out the mechanisms of action of GA.

## 6 **Data extraction**

7 All the searched literature were assessed for the information according to surname of first author,  
8 year of publication, GA, test system, observation, result, concentrations tested and suggested  
9 molecular mechanism involved. The general steps of the data search, the exclusion-inclusion  
10 data and other relevant information are presented in Fig. 2.

## 11 **Literature review**

12 A total number of 2217 reports were revealed under anti-diabetic and cardioprotective effects of  
13 GA using different databases including PubMed, Google Scholar, Web of Science, Science  
14 Direct and Scopus in which 35 studies met the inclusion criteria. The exclusion of 2182  
15 documents was because of duplication of information, absence of any title and non-relevance of  
16 the study.

## 17 **Anti-diabetic effect of GA**

18 DM is a chronic metabolic disorder characterized by hyperglycemia as a results of reduction  
19 of secretion and action of insulin.<sup>[26]</sup> A number of complications are directly linked with DM  
20 including neuropathy, cardiovascular (micro and macro vascular) diseases and nephropathy  
21 through affecting body's antioxidant mechanisms.<sup>[6]</sup> A number of reports confirmed that the  
22 excessive production of ROS and oxidative stress plays an essential role in the progression of

1 diabetes and its complications through alteration of lipid peroxide production, antioxidant  
2 enzyme levels, auto-oxidation of glucose, glutathione metabolism, formation of AGEs as well as  
3 alteration of several signaling pathways in different tissues.<sup>[27, 28]</sup> A number of phytomedicines  
4 and herbal preparations have long been evaluated to develop natural product based new anti-  
5 diabetic drug. GA is a natural dietary triphenolic antioxidant that has diverse bioactivity  
6 including radical scavenging activity, inhibition of lipid peroxidation (LPO), metal ion chelation,  
7 maintenance of endogenous defence system and interfering cell signaling pathways.<sup>[29]</sup> Literature  
8 study demonstrated that GA has the ability to decrease the harmful consequences in diabetic rats  
9 via altering biochemical and histopathological biomarkers of oxidative stress as well as affecting  
10 a number of cellular signaling pathways. It also showed protection of pancreatic  $\beta$ -cell, increased  
11 cellular glucose uptake as well as increase plasma insulin secretion and insulin sensitivity (Table  
12 2). Table 2 and 4 summarized the anti-diabetic effect of GA in both *in-vivo* and *in-vitro* test  
13 models. A number of possible mechanisms for anti-diabetic effect of GA is shown in Fig. 3.

14 *In vivo* experiments of GA revealed that GA has the ability to alter different biochemical  
15 parameters in diabetic animals. A number of reports demonstrated that treatment of GA at a dose  
16 of 10-20 mg/kg b.w. in streptozotocin (STZ) induced diabetic rats can reduce blood glucose level,  
17 total cholesterol (TC), triglyceride (TG), uric acid (UA) and serum creatinine (SC), while  
18 increasing plasma insulin (PI), C-peptide and glucose tolerance level.<sup>[30, 31]</sup> In 2014, Kade, *et al.*,  
19 showed that GA mitigates pancreatic dysfunction by its anti-oxidative effect (increased vit C,  
20 glutathione,  $Fe^{2+}$  chelation and  $Fe^{3+}$  reduction ability of pancreas) and enhances glucose uptake  
21 in STZ-induced oxidative stressed rat.<sup>[32]</sup> Another report by Ramkumar, *et al.*, (2014) showed  
22 protective effect of GA on alloxan-induced oxidative stressed diabetic rats via scavenging of  
23 ROS, upregulation of antioxidant enzymes (catalase (CAT), superoxide dismutase (SOD),



1 glutathione peroxides (GPx)) and increased insulin secretion.<sup>[33]</sup> Other report by Al-Salih et  
2 al.(2010) showed synergistic effect of GA with tannic acid that decreased blood glucose level  
3 and serum malondialdehyde (MDA) level in alloxan induced female diabetic rabbits and *in-vitro*  
4 rat pancreas homogenate.<sup>[34, 35]</sup> It is reported that MDA is the accumulated ROS induced  
5 oxidative breakdown product of phospholipid which has key role in modifying low density  
6 lipoprotein (LDL), non-enzymatic and auto-oxidative glycosylation as well as act as a surrogate  
7 marker of oxidative stress in diabetics.<sup>[36]</sup>

8 Peroxisome proliferator-activated receptors- alpha, beta, gamma (PPAR- $\alpha$ ,  $\beta$ ,  $\gamma$ ) are nuclear  
9 receptor proteins that play an essential role in the regulation of glucose and fat metabolism.<sup>[37]</sup> A  
10 number of anti-diabetic drugs such as thiazolidinediones (TZDs) exert their action (increased  
11 insulin sensitivity) via interacting with PPAR- $\gamma$ .<sup>[38]</sup> PGC1 $\alpha$  is another protein that interact with  
12 PPAR- $\gamma$  to control a number of transcription factors which helps to regulate mitochondrial  
13 biogenesis, oxidative metabolism as well as inhibits pro-inflammatory cytokine production.<sup>[39-42]</sup>  
14 AMP-activated protein kinase (AMPK) has a key role in cellular glucose and fatty acid uptake  
15 via translocation of GLUT4 in the plasma membrane<sup>[41, 43, 44]</sup> and inducing mitochondrial  
16 biogenesis by regulating peroxisome proliferator-activated receptor gamma coactivator 1-alpha  
17 (PGC1 $\alpha$ ).<sup>[45]</sup> AMPK also facilitate cellular fatty acid oxidation via upregulation and activation of  
18 PPAR- $\alpha$ , PGC1 $\alpha$  and UCP.<sup>[46, 47]</sup> Mitochondrial uncoupling proteins (UCP2) help to control of  
19 mitochondria-derived ROS production.<sup>[48-50]</sup> Studies have shown that one of the mechanisms of  
20 AMPK action in maintaining intracellular redox regulation is to up-regulate the expression of  
21 mitochondrial UCP2 and SOD.<sup>[51, 52]</sup> Therefore, these proteins play a crucial role in glucose and  
22 fat metabolism as well as reducing cellular oxidative stress. Any molecules that interact with  
23 these key proteins could be important in the prevention and management of DM. Interestingly, a

1 number of reports studied and found that GA has the ability to alter a number of such cellular  
2 signaling pathways to exhibit its anti-diabetic action. A number of *in vivo* experiments  
3 demonstrated anti-diabetic effect of GA through the increase in glucose uptake, insulin  
4 sensitivity, adipocytokines as well as reduction in adipocyte hypertrophy caused by the  
5 upregulation of cellular PPAR- $\gamma$  expression and translocation of GLUT4 in Akt signaling  
6 pathway in high fat diet induced hyperglycemic mice and rat.<sup>[53-55]</sup> Another interesting report  
7 showed that GA plays an important role in glucose and insulin homeostasis as well as  
8 thermogenesis through the activation of AMPK and by regulating mitochondrial function via the  
9 activation of PGC1 $\alpha$  as well as elevation of UCP2 together with other genes related to energy  
10 expenditure in the brown adipose tissue.<sup>[56]</sup> Several *in vitro* experimental studies done in cultured  
11 cell lines and pancreatic cell homogenate (3T3-L1, RINm5F, isolated rat pancreas) showed that  
12 GA has the ability to induce GLUT4 translocation and glucose uptake activity, inhibit  $\alpha$ -amylase  
13 and  $\alpha$ -glucosidase, increases insulin secretion and prevent insulin amyloid fibril formation in the  
14 cultured cell lines which were further supported by *in vivo* studies reported elsewhere.<sup>[35, 57-59]</sup>

15 From the above literature study, it is clear that GA exerts anti-diabetic effects not only by its  
16 antioxidant mechanism but also by inducing PPAR $\gamma$  and PGC1 $\alpha$  expression, activating AMPK  
17 and Akt signaling pathway as well as enhancing glucose uptake through translocation and  
18 activation of GLUT4. GA further prevents mitochondrial dysfunction through upregulation of  
19 UCP proteins which leads to improve oxidative stress along with improved glucose metabolism  
20 and insulin resistance and ultimately showing anti-diabetic effect (Fig. 3).

### 21 **Cardioprotective effect of GA**

22 CVDs such as coronary artery disease, hypertensive heart diseases, and stroke are  
23 attributed for most of the mortalities around the world.<sup>[60]</sup> It is well established that DM increases

1 the incidence of CVDs and a major risk factor for the development of CVDs.<sup>[61-63]</sup> Clinical  
2 studies showed that patients with type II DM possesses a number of risk factors for the  
3 development of CVDs including hyperglycemia, abnormalities of inflammatory mediators, lipid  
4 profiles and thrombolytic parameters, as well as other abnormalities associated with insulin  
5 resistance.<sup>[61]</sup> A significant number of studies over the last few decades confirmed that oxidative  
6 stress-related factor such as ROS, play an important role in the pathophysiology of CVDs and  
7 DM.<sup>[60, 64]</sup> Clinical studies also demonstrated that antioxidant balance is a key indicator for  
8 diabetes induced myocardial damage and patients with diabetes and myocardial infraction (D-  
9 MI) exhibit high level of total cholesterol (TC), triglycerides (TG), low-densitylipoprotein (LDL),  
10 cardiac markers such as creatine phosphokinase (CPK), creatine kinase-MB (CK-MB), aspartate  
11 aminotransferase (AST), C-reactive protein (CRP), lactate dehydrogenase (LDH), troponin-I  
12 (TnI) as well as low level of oxidative stress marker such as high-density lipoprotein (HDL),  
13 superoxide dismutase (SOD), glutathione (GSH), malondialdehyde (MDA), catalase (CAT) in  
14 comparison to non-myocardial infraction (N-MI) patients.<sup>[65, 66]</sup> Therefore, antioxidant based  
15 interventions are an important tool to treat diabetes and associated CVDs. Natural polyphenols  
16 are one of the prominent antioxidants that has been reported to manage efficiently CVDs and  
17 DM.<sup>[67, 68]</sup>

18 GA is a bioactive natural polyphenolic acid and possesses strong antioxidant activity.  
19 Over the last decade, a number of significant studies have been conducted on the health  
20 beneficial effects of GA including its cardioprotective and anti-diabetic activities. Table 3 and 4  
21 summarizes the cardioprotective effects of GA done in *in-vivo* or *in-vitro* test models. Elevation  
22 of lipid peroxidation in experimental myocardial infarction is an established phenomenon caused  
23 by oxidative modification of lipids by ROS as a results of cell damage and alterations in the

1 function of membrane proteins including ion channels, enzymes and receptors as well as  
2 produced pro-atherogenic and pro-inflammatory mediated toxic products.<sup>[69, 70]</sup> Clinically, CK,  
3 CK-MB, LDH, AST and ALT are found in the cardiac tissues that played different functions and  
4 act as a biomarker for damage of cardiac tissues by ROS and LPO such as in myocardial  
5 infarction whereas CRP and MDA are the products of inflammation and lipid peroxidation which  
6 act as a marker of oxidative stress.<sup>[71-73]</sup> SOD, GPx, CAT are the first line defence antioxidants  
7 that play an indispensable role in the protective effect of cells against ROS and lipid  
8 peroxidation.<sup>[74]</sup> Literature study revealed that GA showed cardioprotective effect through  
9 improving antioxidant defence mechanisms *via* upregulation of enzymatic (CAT, SOD, GPx,  
10 glutathione reductase (GR) and glutathione-S-transferase (GST)) and non-enzymatic (GSH, Vit.  
11 C and E) antioxidants, reduction of LPO i.e. attenuates levels of TG, TC, LDL, very low density  
12 lipoprotein (VLDL) and MDA as well as downregulation of the activity of cardiac biomarkers  
13 (CK, CK-MB, AST, alanine transaminase (ALT), LDH, CRP and TnI) either in isoproterenol  
14 (ISO), STZ, doxorubicin (DOX), alumina (Al<sub>2</sub>O<sub>3</sub>), AGEs, cobalt chloride (CoCl<sub>2</sub>), diazinon,  
15 sodium fluoride (NaF), isoprenaline or cyclophosphamide (CYP)-induced cardiotoxicity in rat  
16 model.<sup>[75-85]</sup> DM increases the incident of CVDs development and interestingly GA showed  
17 cardioprotective effect through inhibition of LPO and boosting antioxidant defence mechanisms  
18 in STZ or alloxan-induced diabetic rat model.<sup>[76, 86]</sup> GA showed cardioprotective effect when  
19 given orally in different doses (15-120 mg/kg/daily b.w for 1-4 weeks) to experimentally induced  
20 myocardial infarcted rats.<sup>[75-85]</sup> Badavi, M., *et al.* (2014) and Ramezani-Aliakbari, *et al.* (2017)  
21 also found the attenuation of antioxidant defence mechanisms by different doses of GA in  
22 ischemic reperfusion in isolated rat heart tissue.<sup>[86, 87]</sup>

1           Lysosomal enzymes such as  $\beta$ -glucuronidase,  $\beta$ -*N*-acetylglucosaminidase,  $\beta$ -  
2 galactosidase, also play important roles in the normal turnover of tissue proteins and other  
3 macromolecules. These enzymes are also responsible for alterations in the rate of degradation of  
4 many tissue components such as abnormal release and activation of lysosomal enzymes during  
5 ischemia.<sup>[88]</sup> Along with improving antioxidant defence mechanisms and reduction of LPO, GA  
6 has been reported to improve myocardial infraction via downregulation of liposomal enzymes in  
7 ISO-treated myocardial infarcted rats.<sup>[89]</sup> It is reported that the gap junction protein Connexin 43  
8 (Cx43) can express in connective tissues, inflammatory cells and vascular elements that help to  
9 reduces ventricular tachycardia (VT) incidence following myocardial infraction.<sup>[90]</sup>  $\text{Na}^+/\text{K}^+$   
10 ATPase (Sodium-potassium adenosine triphosphatase) is another enzyme found in all cell  
11 membrane that helps to maintain resting potential, transport, cell volume as well as signal  
12 transduction to regulate mitogen-activated protein kinases (MAPKs) and ROS pathway.<sup>[91]</sup> In  
13 myocardial tissues, there is a correlation between decrease in heart function and decreased  
14 concentration of  $\text{Na}^+/\text{K}^+$  ATPase.<sup>[92]</sup> El-Hussainy *et al.*, (2016) and Padma *et al.*, (2012) showed  
15 that GA has the ability to protect myocardial injury via upregulation of Cx43 and  $\text{Na}^+/\text{K}^+$   
16 ATPase in alumina or lindane induced myocardial injury in rats.<sup>[78, 93]</sup> Furthermore, cellular  
17 MAPKs signaling pathway is responsible to control a vast array of physiological processes. MAP  
18 kinase family such as c-Jun N-terminal kinases (JNKs), extracellular signal–regulated kinases  
19 (ERKs), p38 play key role to regulated MAPKs pathway by activating one another and help to  
20 control cell division (by ERKs) or transcription (by JNKs).<sup>[94]</sup> Inflammatory cytokines, growth  
21 factors, oxidative stress by ROS, protein synthesis inhibitors, and other stress stimuli can activate  
22 MAPKs family.<sup>[95]</sup> Activation of MAPKs system through oxidative stress (excess ROS) has  
23 key role for the formation of AGEs that takes part in pathogenesis of myocardial toxicity and

1 accelerate atherosclerosis in DM.<sup>[96-98]</sup> AGEs also induce myocardial fibrosis through activation  
2 of extracellular matrix protein (ECR) such as collagen.<sup>[99]</sup> Smads (or SMADs) are another  
3 protein family that are the main signal transducers for receptors of transforming growth factor  
4 beta (TGF- $\beta$ ) and downregulation of TGF- $\beta$ /Smads can induce accumulation of extracellular  
5 matrix (ECM) proteins such as collagen and promote cellular fibrosis.<sup>[100]</sup> Interestingly, literature  
6 study demonstrated that GA can prevent ISO-induced cardiac hypertrophy and fibrosis by  
7 improved oxidative stress and inhibition of collagen deposition via down regulation of JNK2,  
8 ERK signaling pathway and Smad3 binding activity in GA treated mice.<sup>[101]</sup> Later, Jin et al.,  
9 (2017) confirmed that GA can attenuate cardiac remodeling and fibrosis in *N*-nitro-L-arginine  
10 methyl ester (L-NAME)-induced hypertensive mice through downregulation of ECM such as  
11 collagen type I, collagen type III, and connective tissue growth factor (CTGF).<sup>[102]</sup> However,  
12 Akinrinde, *et al.*, (2016) reproted that the protective effects of GA against CoCl<sub>2</sub> -induced  
13 cardiorenal dysfunction via suppression of oxidative stress and activation of the ERK signaling  
14 pathway.<sup>[80]</sup> Recent study by Jin, *et al.* (2017) reported that GA attenuates hypertension and  
15 cardiac hypertrophy in both *in-vitro* and *in vivo* test models.<sup>[102, 103]</sup> *In vitro* cardioprotective  
16 studies of GA were mainly conducted (10-100  $\mu$ M) in cultured rat neonatal cardiomyocytes  
17 H9c2(2-1) cells treated by different agents such as AGE, L-NAME, ISO and renin-angiotensin II  
18 (Table 4). *In vitro* data also demonstrated that GA has the ability to reduce cardiotoxicity through  
19 inhibition of cell proliferation, elevation of cellular antioxidant mechanisms, inhibition of LPO  
20 and downregulation of JNK, Samds and GATA4-induced NADPH oxidase (Nox) signaling  
21 pathway following reduction of AGE-induced cytokines (tumor necrosis factor-alpha (TNF- $\alpha$ ),  
22 TGF- $\beta$ , inducible nitric oxide synthase (iNOS)) and matrix proteins, receptor for AGE (RAGE),  
23 tissue inhibitor metalloproteinase (TIMPs), matrix metalloproteinase (MMP)) of cultured

1 cells.<sup>[101-105]</sup> The *in vitro* results also support the *in vivo* cardioprotective data as mentioned in  
2 proposed mechanism of action of GA in fig. 3.

3

#### 4 **Conclusion**

5 GA is a very common dietary plant constituent possessing strong antioxidant proprieties and  
6 used in several herbal formulations to treat different diseases. In this review, we have  
7 summarized the anti-diabetic and cardioprotective reports of GA published to-date. Studies done  
8 in *in vivo* and *in vitro* test models clearly demonstrated anti-diabetic and cardioprotective  
9 potential of GA. Such activities of GA were exerted through improving cellular antioxidant  
10 defence mechanisms, inhibiting lipid peroxidation as well as regulation of different key proteins  
11 related to DM and CVDs. A number of interesting studies were also found where GA showed  
12 significant protection against diabetes and diabetes induced myocardial damage. To conclude,  
13 the antioxidants based interventions as well as upregulation of key proteins was the major  
14 pathway for anti-diabetic activity of GA. Therefore, it is evident that GA can be considered as  
15 promising dietary lead molecule for the prevention of diabetes. The anti-diabetic studies on GA  
16 conducted over the last few years were mainly *in vivo* or *in vitro* models and data-related  
17 preclinical or clinical trials for such activities still remains absent. Thus, more clinical and  
18 pharmacokinetic investigation on GA is important to conclude on the anti-diabetic and  
19 cardioprotective potential of GA.

#### 20 **Author Contribution**

21 The paper was designed by SJU and written by SJU, MF and SMNKZ. MSR, SA, INK and  
22 SMSAR did the molecular mechanism discussion. RR, MTI, JAS, LN, ET and SDS provided  
23 valuable guidance, revision, correction and other insight into the work.

1 **Conflict of Interest**

2 We wish to confirm that there are no known conflicts of interest associated with this publication  
3 and there has been no significant financial support for this work that could have influenced its  
4 outcome.

5 **Funding**

6 We wish to confirm that there is no significant financial support available for this study.

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22



## 1 **References**

- 2 [1] Einarson, T. R.; Acs, A.; Ludwig, C.; Panton, U. H. Prevalence of Cardiovascular Disease  
3 in Type 2 Diabetes: A Systematic Literature Review of Scientific Evidence from Across the  
4 World in 2007-2017. *Cardiovasc. Diabetol.* **2018**, *17*(1), 83-83.
- 5 [2] Global Health Estimates 2016: *Disease burden by Cause, Age, Sex, by Country and by*  
6 *Region, 2000-2016*, Geneva, World Health Organization, 2016.
- 7 [3] Danaei, G.; Finucane, M. M.; Lu, Y.; Singh, G. M.; Cowan, M. J.; Paciorek, C. J.; Lin, J. K.;  
8 Farzadfar, F.; Khang, Y. H.; Stevens, G. A. National, Regional, and Global Trends in  
9 Fasting Plasma Glucose and Diabetes Prevalence Since 1980: Systematic Analysis of Health  
10 Examination Surveys and Epidemiological Studies with 370 Country-Years and 2· 7 Million  
11 Participants. *Lancet.* **2011**, *378*(9785),31-40.
- 12 [4] Leon, B. M.; Maddox, T. M. Diabetes and Cardiovascular Disease: Epidemiology, Biological  
13 Mechanisms, Treatment Recommendations and Future Research. *World J. Diabetes.* **2015**,  
14 *6*(13), 1246-1258.
- 15 [5] Wahren, J.; Felig, P.; Cerasi, E.; Luft, R. Splanchnic and Peripheral Glucose and Amino Acid  
16 Metabolism in Diabetes Mellitus. *J. Clin. Invest.* **1972**, *51*(7), 1870-1878.
- 17 [6] Moree, S. S.; Kavishankar, G.; Rajesha, J. Antidiabetic Effect of Secoisolariciresinol  
18 Diglucoside in Streptozotocin-Induced Diabetic Rats. *Phytomedicine.* **2013**, *20*(3-4), 237-  
19 245.
- 20 [7] Battiprolu, P. K.; Gillette, T. G.; Wang, Z. V.; Lavandero, S.; Hill, J. A. Diabetic  
21 Cardiomyopathy: Mechanisms and Therapeutic Targets. *Drug Discov.Today.* **2010**, *7*(2),  
22 135-143.
- 23 [8] Singh, V. P.; Bali, A.; Singh, A.; Jaggi, A. S. Advanced Glycation End Products and Diabetic  
24 Complications. *Korean J. Physiol. Pharmacol.* **2014**, *18*(1), 1-14.
- 25 [9] Iacobellis, G.; Ribaldo, M. C.; Zappaterreno, A.; Iannucci, C. V.; Leonetti, F. Relation  
26 Between Epicardial Adipose Tissue and Left Ventricular Mass. *Am. J. Cardiol.* **2004**, *94*(8),  
27 1084-1087.
- 28 [10] Ahmed, N. Advanced Glycation Endproducts—Role in Pathology of Diabetic  
29 Complications. *Diabetes Res. Clin. Pr.* **2005**, *67*(1), 3-21.
- 30 [11] Graham, I.; Atar, D.; Borch-Johnsen, K.; Boysen, G.; Burell, G.; Cifkova, R. Dallongeville,  
31 J.; De Backer, G.; Ebrahim, S.; Gjelsvik, B. European Guidelines on Cardiovascular Disease  
32 Prevention in Clinical Practice: Executive Summary: Fourth Joint Task Force of the  
33 European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention  
34 in Clinical Practice (Constituted by Representatives of Nine Societies and by Invited  
35 Experts). *Eur. Heart J.* **2007**, *28*(19), 2375-2414.
- 36 [12] Hemingway, R. W.; Laks, P. E. *Plant Polyphenols: Synthesis, Properties, Significance*;  
37 Springer Science & Business Media, 2012.
- 38 [13] Pandurangan, A. K.; Moheballi, N.; Norhaizan, M. E.; Looi, C. Y. Gallic Acid Attenuates  
39 Dextran Sulfate Sodium-Induced Experimental Colitis in Balb/C Mice. *Drug Des. Dev.*  
40 *Ther.* **2015**, *9*, 3923.

- 1 [14] Koyama, K.; Goto-Yamamoto, N.; Hashizume, K. Influence of Maceration Temperature in  
2 Red Wine Vinification on Extraction of Phenolics from Berry Skins and Seeds of Grape  
3 (*Vitis vinifera*). *Biosci. Biotech. Bioch.* **2007**, *71*(4), 958-965.
- 4 [15] Hodgson, J. M., Morton, L. W.; Puddey, I. B.; Beilin, L. J.; Croft, K. D. Gallic Acid  
5 Metabolites are Markers of Black Tea Intake in Humans. *J. Agr. Food Chem.* **2000**, *48*(6),  
6 2276-2280.
- 7 [16] Pathak, S.; Niranjana, K.; Padh, H.; Rajani, M. TLC Densitometric Method for the  
8 Quantification of Eugenol and Gallic Acid in Clove. *Chromatographia.* **2004**, *60*(3-4),  
9 241-244.
- 10 [17] Gálvez, M. C.; Barroso, C. G.; Pérez-Bustamante, J. A. Analysis of Polyphenolic  
11 Compounds of Different Vinegar Samples. *Z. Lebensmittel-Untersuchung Forsch.* **1994**,  
12 *199*(1), 29-31.
- 13 [18] Madlener, S.; Illmer, C.; Horvath, Z.; Saiko, P.; Losert, A.; Herbacek, I.; Grusch, M.;  
14 Elford, H. L.; Krupitza, G.; Bernhaus, A. Gallic Acid Inhibits Ribonucleotide Reductase and  
15 Cyclooxygenases in Human HL-60 Promyelocytic Leukemia Cells. *Cancer Let.* **2007**, *245*(1-  
16 2), 156-162.
- 17 [19] Pal, S. M.; Avneet, G.; Siddhraj, S. S. Gallic Acid: Pharmacological Promising Lead  
18 Molecule: A Review. *Int. J. Pharmacog. Phytochem. Res.* **2018**, *10*(4),132-138.
- 19 [20] Roberts, A. T.; Martin, C. K.; Liu, Z.; Amen, R. J.; Woltering, E. A.; Rood, J. C.; Caruso,  
20 M. K.; Yu, Y.; Xie, H.; Greenway, F. L. The Safety and Efficacy of a Dietary Herbal  
21 Supplement and Gallic Acid for Weight Loss. *J. Med. Food.* **2007**, *10*(1), 184-188.
- 22 [21] Mämmelä, P.; Savolainen, H.; Lindroos, L.; Kangas, J.; Vartiainen, T. Analysis of Oak  
23 Tannins by Liquid Chromatography-Electrospray Ionisation Mass Spectrometry. *J.*  
24 *Chromatogr.* **2000**, *A 891*(1),75-83.
- 25 [22] Alemika, T. E.; Onawunmi, G. O.; Olugbade, T. Antibacterial Phenolics from *Boswellia*  
26 *dalzielii*, *Nigerian J. Nat. Prod. Med.* **2006**, *10*(1), 108-110.
- 27 [23] Chanwitheesuk, A.; Teerawutgulrag, A.; Kilburn, J. D.; Rakariyatham, N. Antimicrobial  
28 Gallic Acid from *Caesalpinia mimosoides* Lamk, *Food Chem.* **2007**, *100*(3), 1044-1048.
- 29 [24] Roberts, A. T.; Martin, C. K.; Liu, Z.; Amen, R. J.; Woltering, E. A.; Rood, J. C.; Caruso,  
30 M. K.; Yu, Y.; Xie, H.; Greenway, F. L. The Safety and Efficacy of a Dietary Herbal  
31 Supplement and Gallic Acid for Weight Loss. *J. Med. Food.* **2007**, *10*(1),184-8.
- 32 [25] Borde, V.; Pangrikar, P.; Tekale, S. Gallic Acid in Ayurvedic Herbs and Formulations. *Rec.*  
33 *Res. Sci.Tech.* **2011**, *3*(7).
- 34 [26] Samad, N.; Javed, A. Therapeutic Effects of Gallic Acid: Current Scenario. *J. Phytochem.*  
35 *Biochem.* **2018**, *2*, 113.
- 36 [27] Volpe, C. M. O.; Villar-Delfino, P. H.; Dos Anjos, P. M. F.; Nogueira-Machado, J. A.  
37 Cellular Death, Reactive Oxygen Species (Ros) and Diabetic Complications. *Cell Death Dis.*  
38 **2018**, *9*(2), 119-119.
- 39 [28] Farkhondeh, T.; Samarghandian, S.; Borji, A. An Overview on Cardioprotective and Anti-  
40 Diabetic Effects of Thymoquinone. *Asian Pac. J. Trop. Med.* **2017**, *10*(9), 849-854.

- 1 [29] Badhani, B.; Sharma, N.; Kakkar, R. Gallic Acid: A Versatile Antioxidant with Promising  
2 Therapeutic and Industrial Applications. *RSC Adv.* **2015**, 5(35), 27540-27557.
- 3 [30] Latha, R. C. R.; Daisy, P. Insulin-secretagogue, Antihyperlipidemic and other Protective  
4 Effects of Gallic Acid Isolated from *Terminalia bellerica* Roxb. in streptozotocin-induced  
5 Diabetic Rats. *Chem-Biol. Interact.* **2011**, 189(1-2), 112-118.
- 6 [31] Punithavathi, V. R.; Prince, P. S. M.; Kumar, R.; Selvakumari, J. Antihyperglycaemic,  
7 Antilipid Peroxidative and Antioxidant Effects of Gallic Acid on Streptozotocin Induced  
8 Diabetic Wistar Rats. *Eur.J. Pharmacol.* **2011**, 650(1), 465-471.
- 9 [32] Kade, I. J.; Ogunbolude, Y.; Kamdem, J. P.; Rocha, J. B. T. Influence of Gallic Acid on  
10 Oxidative Stress-Linked Streptozotocin-Induced Pancreatic Dysfunction in Diabetic Rats. *J*  
11 *Basic Clin. Physiol. Pharmacol.* **2014**, 25(1), 35-45.
- 12 [33] Ramkumar, K.; Vijayakumar, R.; Vanitha, P.; Suganya, N.; Manjula, C.; Rajaguru, P.;  
13 Sivasubramanian, S.; Gunasekaran, P. Protective Effect of Gallic Acid on Alloxan-Induced  
14 Oxidative Stress and Osmotic Fragility in Rats. *Human Exp.Toxicol.* **2014**, 33(6), 638-649.
- 15 [34] Al-Salih, R. M. Clinical Experimental Evidence: Synergistic Effect of Gallic Acid And  
16 Tannic Acid as Antidiabetic and Antioxidant Agents. *Thi-Qar Med. J.* **2010**, 4(4), 109-119.
- 17 [35] Adefegha, S. A.; Oboh, G.; Ejakpovi, I. I.; Oyeleye, S. I. Antioxidant and Antidiabetic  
18 Effects of Gallic and Protocatechuic Acids: A Structure–Function Perspective. *Compar.*  
19 *Clin. Pathol.* **2015**, 24(6), 1579-1585.
- 20 [36] Bhutia, Y.; Ghosh, A.; Sherpa, M. L.; Pal, R.; Mohanta, P. K. Serum Malondialdehyde  
21 Level: Surrogate Stress Marker in the Sikkimese Diabetics. *J. Nat. Sci. Biol. Med.* **2011**,  
22 2(1), 107-112.
- 23 [37] Moller, D. E. The Mechanisms of Action of PPARs. *Annu. Rev. Med.* **2002**, 53(1), 409-435.
- 24 [38] Thangavel, N.; Al Bratty, M.; Akhtar Javed, S.; Ahsan, W.; Alhazmi, H. A. Targeting  
25 Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design  
26 of Novel Antidiabetic Drugs. *Int. J. Med. Chem.* **2017**, 2017 20.
- 27 [39] Lin, J.; Wu, H.; Tarr, P. T.; Zhang, C. Y.; Wu, Z.; Boss, O.; Michael, L. F.; Puigserver, P.;  
28 Isotani, E.; Olson, E. N.; Lowell, B. B.; Bassel-Duby, R.; Spiegelman, B. M. Transcriptional  
29 Co-Activator Pgc-1 $\alpha$  Drives the Formation of Slow-Twitch Muscle Fibres. *Nature.* **2002**,  
30 418(6899), 797-801.
- 31 [40] Vats, D.; Mukundan, L.; Odegaard, J. I.; Zhang, L.; Smith, K. L.; Morel, C. R.; Greaves, D.  
32 R.; Murray, P. J.; Chawla, A. Oxidative Metabolism And Pgc-1beta Attenuate Macrophage-  
33 Mediated Inflammation. *Cell Metab.* **2006**, 4(1), 13-24.
- 34 [41] Claret, M.; Smith, M. A.; Batterham, R. L.; Selman, C.; Choudhury, A. I.; Fryer, L. G. D.;  
35 Clements, M.; Al-Qassab, H.; Heffron, H.; Xu, A. W.; Speakman, J. R.; Barsh, G. S.;  
36 Viollet, B.; Vaulont, S.; Ashford, M. L. J.; Carling, D.; Withers, D. J. AMPK is Essential for  
37 Energy Homeostasis Regulation and Glucose Sensing by POMC and AgRP Neurons. *J.*  
38 *Clin. Invest.* **2007**, 117(8), 2325-2336.
- 39 [42] Moreno-Santos, I.; Pérez-Belmonte, L. M.; Macías-González, M.; Mataró, M. J.; Castellano,  
40 D.; López-Garrido, D.; Porrás-Martín, C.; Sánchez-Fernández, P. L.; Gómez-Doblas, J. J.;  
41 Cardona, F.; de Teresa-Galván, E.; Jiménez-Navarro, M.; Type 2 Diabetes is Associated

- 1 with Decreased Pgc1 $\alpha$  Expression in Epicardial Adipose Tissue of Patients with Coronary  
2 Artery Disease. *J. Transl. Med.* **2016**, *14*(1), 243-243.
- 3 [43] Sun, G.; Tarasov, A. I.; McGinty, J.; McDonald, A.; da Silva Xavier, G.; Gorman, T.;  
4 Marley, A.; French, P. M.; Parker, H.; Gribble, F.; Reimann, F.; Prendiville, O.; Carzaniga,  
5 R.; Viollet, B.; Leclerc, I.; Rutter, G. A. Ablation of AMP-Activated Protein Kinase  $\alpha$ 1 and  
6  $\alpha$ 2 from Mouse Pancreatic Beta Cells And *Rip2.Cre* Neurons Suppresses Insulin Release *In*  
7 *Vivo. Diabetol.* **2010**, *53*(5), 924-936.
- 8 [44] Kurth-Kraczek, E. J.; Hirshman, M. F.; Goodyear, L. J.; Winder, W. W. 5' AMP-Activated  
9 Protein Kinase Activation Causes Glut4 Translocation in Skeletal Muscle. *Diabetes.* **1999**,  
10 *48*(8),1667-71.
- 11 [45] Jeon, S. M. Regulation and Function of AMPK in Physiology and Diseases. *Exp. Mol. Med.*  
12 **2016**, *48*(7), 245-245.
- 13 [46] Lee, W. J.; Kim, M.; Park, H. S.; Kim, H. S.; Jeon, M. J.; Oh, K. S.; Koh, E. H.; Won, J. C.;  
14 Kim, M. S.; Oh, G. T.; Yoon, M.; Lee, K. U.; Park, J. Y. AMPK Activation Increases Fatty  
15 Acid Oxidation in Skeletal Muscle by Activating PPAR $\alpha$  and PGC-1. *Biochem. Biophys.*  
16 *Res. Commun.* **2006**, *340*(1), 291-5.
- 17 [47] Ojuka, E. O.; Nolte, L. A.; Holloszy, J. O. Increased Expression of Glut-4 and Hexokinase  
18 in Rat Epitrochlearis Muscles Exposed to AICAR *in vitro.* *J. Appl. Physiol.* **2000**, *88*(3),  
19 1072-1075.
- 20 [48] Arsenijevic, D.; Onuma, H.; Pecqueur, C.; Raimbault, S.; Manning, B. S.; Miroux, B.;  
21 Couplan, E.; Alves-Guerra, M. C.; Goubern, M.; Surwit, R.; Bouillaud, F.; Richard, D.;  
22 Collins, S.; Ricquier, D.; Disruption of the Uncoupling Protein-2 Gene in Mice Reveals a  
23 Role in Immunity and Reactive Oxygen Species Production. *Nat. Genet.* **2000**, *26*(4), 435-  
24 439.
- 25 [49] Mailloux, R. J.; Harper, M. E. Uncoupling Proteins and the Control of Mitochondrial  
26 Reactive Oxygen Species Production, *Free Rad. Biol. Med.* **2011**, *51*(6), 1106-1115.
- 27 [50] Brand, M. D.; Esteves, T. C. Physiological Functions of the Mitochondrial Uncoupling  
28 Proteins UCP2 and UCP3. *Cell Metab.* **2005**, *2*(2), 85-93.
- 29 [51] Calegari, V. C.; Zoppi, C. C.; Rezende, L. F.; Silveira, L. R.; Carneiro, E. M.; Boschero, A.  
30 C. Endurance Training Activates AMP-Activated Protein Kinase, Increases Expression of  
31 Uncoupling Protein 2 and Reduces Insulin Secretion from Rat Pancreatic Islets. *J.*  
32 *Endocrinol.* **2011**, *208*(3), 257-64.
- 33 [52] Wang, S.; Song, P.; Zou, M. H. AMP-Activated Protein Kinase, Stress Responses and  
34 Cardiovascular Diseases. *Clin. Sci.* **2012**, *122*(12), 555-573.
- 35 [53] Gandhi, G. R.; Jothi, G.; Antony, P. J.; Balakrishna, K.; Paulraj, M. G.; Ignacimuthu, S.;  
36 Stalin, A.; Al-Dhabi, N. A. Gallic Acid Attenuates High-Fat Diet Fed-Streptozotocin-  
37 Induced Insulin Resistance via Partial Agonism of PPAR $\gamma$  In Experimental Type 2 Diabetic  
38 Rats And Enhances Glucose Uptake Through Translocation and Activation of Glut4 In  
39 PI3k/P-Akt Signaling Pathway. *Eur. J. Pharmacol.* **2014**, *745*, 201-216.

- 1 [54] Bak, E. J.; Kim, J.; Jang, S.; Woo, G. H.; Yoon, H. G.; Yoo, Y. J.; Cha, J. H. Gallic Acid  
2 Improves Glucose Tolerance and Triglyceride Concentration in Diet-Induced Obesity Mice.  
3 *Scand. J Clin. Lab. Invest.* **2013**, *73*(8), 607-614.
- 4 [55] Abdel-Moneim, A.; El-Twab, S. M. A.; Yousef, A. I.; Reheim, E. S. A.; Ashour, M. B.  
5 Modulation of Hyperglycemia and Dyslipidemia in Experimental Type 2 Diabetes by Gallic  
6 Acid and p-Coumaric Acid: The Role of Adipocytokines and PPAR $\gamma$ . *Biomed.*  
7 *Pharmacother.* **2018**, *105*, 1091-1097.
- 8 [56] Doan, K. V.; Ko, C. M.; Kinyua, A. W.; Yang, D. J.; Choi, Y. H.; Oh, I. Y.; Nguyen, N. M.;  
9 Ko, A.; Choi, J. Y.; Jeong, Y. Gallic Acid Regulates Body Weight and Glucose Homeostasis  
10 Through AMPK Activation. *Endocrinol.* **2015**, *156*(1),157-168.
- 11 [57] Vishnu Prasad, C.; Anjana, T.; Banerji, A.; Gopalakrishnapillai, A. Gallic Acid Induces  
12 Glut4 Translocation and Glucose Uptake Activity in 3T3-L1 Cells. *FEBS Let.* **2010**, *584*(3),  
13 531-536.
- 14 [58] Sameermahmood, Z.; Raji, L.; Saravanan, T.; Vaidya, A.; Mohan, V.; Balasubramanyam,  
15 M.; Gallic Acid Protects RINm5F  $\beta$ -Cells from Glucolipototoxicity by its Aantiapoptotic and  
16 Insulin-secretagogue Actions. *Phytother. Res.* **2010**, *24*(S1), S83-S94.
- 17 [59] Jayamani, J.; Shanmugam, G. Gallic Acid, One of the Components in Many Plant Tissues,  
18 is a Potential Inhibitor for Insulin Amyloid Fibril Formation. *Eur. J. Med.Chem.* **2014**, *85*,  
19 352-358.
- 20 [60] Moris, D.; Spartalis, M.; Spartalis, E.; Karachaliou, G. S.; Karaolani, G. I.; Tsourouflis,  
21 G.; Tsilimigras, D. I.; Tzatzaki, E.; Theocharis, S. The Role of Reactive Oxygen Species in  
22 the Pathophysiology of Cardiovascular Diseases and the Clinical Significance of Myocardial  
23 Redox. *Ann. Transl. Med.* **2017**, *5*(16), 326-326.
- 24 [61] Kalofoutis, C.; Piperi, C.; Kalofoutis, A.; Harris, F.; Phoenix, D.; Singh, J. Type II Diabetes  
25 Mellitus and Cardiovascular Risk Factors: Current Therapeutic Approaches. *Exp. Clin.*  
26 *Cardiol.* **2007**, *12*(1), 17-28.
- 27 [62] Ansley, D. M.; Wang, B. Oxidative Stress and Myocardial Injury in the Diabetic Heart. *J.*  
28 *Pathol.* **2013**, *229*(2), 232-241.
- 29 [63] Boyer, N. M.; Laskey, W. K.; Cox, M.; Hernandez, A. F.; Peterson, E. D.; Bhatt, D. L.;  
30 Cannon, C. P.; Fonarow, G. C. Trends in Clinical, Demographic, and Biochemical  
31 Characteristics of Patients with Acute Myocardial Infarction from 2003 to 2008: A Report  
32 from the American Heart Association Get with the Guidelines Coronary Artery Disease  
33 Program. *J. Am. Heart Asso.* **2012**, *1*(4), e001206.
- 34 [64] Panth, N.; Paudel, K. R.; Parajuli, K. Reactive Oxygen Species: A Key Hallmark of  
35 Cardiovascular Disease. *Adv. Med.* **2016**, 9152732-9152732.
- 36 [65] Ali, F.; Naqvi, S. A. S.; Bismillah, M.; Wajid, N. Comparative Analysis of Biochemical  
37 Parameters in Diabetic and Non-Diabetic Acute Myocardial Infarction Patients. *Indian*  
38 *Heart J.* **2016**, *68*(3), 325-331.
- 39 [66] de Souza Bastos, A.; Graves, D. T.; de Melo Loureiro, A. P.; Júnior, C. R.; Corbi, S. C. T.;  
40 Frizzera, F.; Scarel-Caminaga, R. M.; Câmara, N. O.; Andriankaja, O. M.; Hiyane, M. I.;  
41 Orrico, S. R. P. Diabetes and Increased Lipid Peroxidation are Associated with Systemic

- 1 Inflammation Even in Well-Controlled Patients. *J. Diabetes Complications*. **2016**, 30(8),  
2 1593-1599.
- 3 [67] Aryaeian, N.; Sedehi, S. K.; Arablou, T. Polyphenols and their Effects on Diabetes  
4 Management: A Review. *Med. J. Islam Repub. Iran*. **2017**, 31, 134-134.
- 5 [68] Tangney, C. C.; Rasmussen, H. E. Polyphenols, Inflammation, and Cardiovascular Disease.  
6 *Curr. Atheroscler. Rep*. **2013**, 15(5), 324-324.
- 7 [69] Meerson, F. Z.; Kagan, V. E.; Kozlov Yu, P.; Belkina, L. M.; Arkhipenko Yu, V. The Role  
8 of Lipid Peroxidation in Pathogenesis of Ischemic Damage and the Antioxidant Protection  
9 of the Heart. *Basic Res. Cardiol*. **1982**, 77(5), 465-85.
- 10 [70] Fukuda, K.; Davies Sean, S.; Nakajima, T.; Ong, B. H.; Kupersmidt, S.; Fessel, J.;  
11 Amarnath, V.; Anderson Mark, E.; Boyden Penelope, A.; Viswanathan Prakash, C.; Roberts,  
12 L. J.; Balsler Jeffrey, R. Oxidative Mediated Lipid Peroxidation Recapitulates Proarrhythmic  
13 Effects on Cardiac Sodium Channels. *Circ. Res*. **2005**, 97(12), 1262-1269.
- 14 [71] Gawel, S.; Wardas, M.; Niedworok, E.; Wardas, P. Malondialdehyde (MDA) as a Lipid  
15 Peroxidation Marker. *Wiadomosci lekarskie*. **2004**, 57(9-10), 453-5.
- 16 [72] Pradhan, A. D.; Manson, J. E.; Rifai, N.; Buring, J. E.; Ridker, P. M.; C-Reactive Protein,  
17 Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus, *JAMA*, **2001**, 286(3), 327-  
18 334.
- 19 [73] Mythili, S.; Malathi, N. Diagnostic Markers of Acute Myocardial Infarction, *Biomed. Rep*.  
20 **2015**. 3(6), 743-748.
- 21 [74] Ighodaro, O. M.; Akinloye, O. A. First Line Defence Antioxidants-Superoxide Dismutase  
22 (Sod), Catalase (Cat) and Glutathione Peroxidase (Gpx): Their Fundamental Role in the  
23 Entire Antioxidant Defence Grid. *Alexandria J. Med*. **2018**, 54(4), 287-293.
- 24 [75] Priscilla, D. H.; Prince, P. S. M. Cardioprotective Effect of Gallic Acid on Cardiac  
25 Troponin-T, Cardiac Marker Enzymes, Lipid Peroxidation Products and Antioxidants in  
26 Experimentally Induced Myocardial Infarction in Wistar Rats. *Chem-Biol. Interact*. **2009**,  
27 179(2-3), 118-124.
- 28 [76] Patel, S. S.; Goyal, R. K. Cardioprotective Effects of Gallic Acid in Diabetes-Induced  
29 Myocardial Dysfunction in Rats. *Pharmacog. Res*. **2011**, 3(4), 239.
- 30 [77] Kulkarni, J.; Swamy, A. V. Cardioprotective Effect of Gallic Acid Against Doxorubicin-  
31 Induced Myocardial Toxicity in Albino Rats. *Indian J. Health Sci. Biomed. Res*. **2015**, 8(1),  
32 28.
- 33 [78] El-Hussainy, E. H. M.; Hussein, A. M.; Abdel-Aziz, A.; El-Mehasseb, I. Effects of  
34 Aluminum Oxide (Al<sub>2</sub>O<sub>3</sub>) Nanoparticles on Ecg, Myocardial Inflammatory Cytokines,  
35 Redox State, and Connexin 43 and Lipid Profile in Rats: Possible Cardioprotective Effect of  
36 Gallic Acid. *Can. J. Physiol. Pharmacol*. **2016**, 94(08), 868-878.
- 37 [79] Umadevi, S.; Gopi, V.; Parthasarathy, A; Elangovan, V. Ameliorative Potential of Gallic  
38 Acid on the Activation of ROS and Down-Regulation of Antioxidant Enzymes in Cardiac  
39 Tissue of Rats Infused with Advanced Glycation End Products. *J. Appl. Pharm. Sci*. **2011**,  
40 1(7), 189.

- 1 [80] Akinrinde, A. S.; Omobowale, O.; Oyagbemi, A.; Asenuga, E.; Ajibade, T. Protective  
2 Effects of Kolaviron and Gallic Acid Against Cobalt-Chloride-Induced Cardiorenal  
3 Dysfunction via Suppression of Oxidative Stress and Activation of the Erk Signaling  
4 Pathway. *Can. J. Physiol. Pharmacol.* **2016**, *94*(12), 1276-1284.
- 5 [81] Habtemariam, S.; Sureda, A.; Hajizadeh Moghaddam, A.; Fazel Nabavi, S.; Mohammad  
6 Nabavi, S.; Abolhasani, F. Protective Role of Gallic Acid Isolated from *Peltiphyllum*  
7 *Peltatum* Against Sodium Fluoride-Induced Oxidative Stress in Rat's Heart. *Lett. Drug Des.*  
8 *Discov.* **2013**, *10*(3), 277-282.
- 9 [82] Ogunsanwo, O. R.; Oyagbemi, A. A.; Omobowale, T. O.; Asenuga, E. R.; Saba, A. B.  
10 Biochemical and Electrocardiographic Studies on the Beneficial Effects of Gallic Acid in  
11 Cyclophosphamide-Induced Cardiorenal Dysfunction. *J. Complement. Integr. Med.* **2017**,  
12 *14*(3).
- 13 [83] Bakheet, M. S.; Soltan, S.; Gadalla, A.; Haredy, H. H.; Shakoor, M. A. Antioxidants  
14 (Vitamin E and Gallic Acid) as Valuable Protective Factors Against Myocardial Infarction.  
15 *Basic Res. J. Med. Clin. Sci.* **2014**, *3*, 109-122.
- 16 [84] Omóbòwálé, T. O.; Oyagbemi, A. A.; Folasire, A. M.; Ajibade, T. O.; Asenuga, E. R.;  
17 Adejumobi, O. A.; Ola-Davies, O. E.; Oyetola, O.; James, G.; Adedapo, A. A. Ameliorative  
18 Effect of Gallic Acid on Doxorubicin-Induced Cardiac Dysfunction in Rats. *J. Basic Clin.*  
19 *Physiol. Pharmacol.* **2018**, *29*(1), 19-27.
- 20 [85] Ajibade, T. O.; Oyagbemi, A. A.; Omobowale, T. O.; Asenuga, E. R.; Afolabi, J. M.;  
21 Adedapo, A. A. Mitigation of Diazinon-Induced Cardiovascular and Renal Dysfunction by  
22 Gallic Acid. *Interdiscip. Toxicol.* **2016**, *9*(2), 66-77.
- 23 [86] Ramezani-Aliakbari, F.; Badavi, M.; Dianat, M.; Mard, S. A.; Ahangarpour, A. Effects of  
24 Gallic Acid on Hemodynamic Parameters and Infarct Size After Ischemia-Reperfusion in  
25 Isolated Rat Hearts with Alloxan-Induced Diabetes. *Biomed. Pharmacother.* **2017**, *96*, 612-  
26 618.
- 27 [87] Badavi, M.; Sadeghi, N.; Dianat, M.; Samarbafzadeh, A. Effects of Gallic Acid and  
28 Cyclosporine A on Antioxidant Capacity and Cardiac Markers of Rat Isolated Heart After  
29 Ischemia/Reperfusion. *Iranian Red Cres. Med. J.* **2014**, *16*(6).
- 30 [88] K. Wildenthal, R.S. Decker, The role of lysosomes in the heart, *Advances in myocardiology*  
31 *2* (1980) 349-58.
- 32 [89] Prince, P. S. M.; Priscilla, H.; Devika, P. T. Gallic Acid Prevents Lysosomal Damage in  
33 Isoproterenol Induced Cardiotoxicity in Wistar Rats. *Eur. J. Pharmacol.* **2009**, *615*(1-3),  
34 139-143.
- 35 [90] Roell, W.; Klein, A. M.; Breitbach, M.; Becker, T. S.; Parikh, A.; Lee, J.; Zimmermann, K.;  
36 Reining, S.; Gabris, B.; Ottersbach, A.; Doran, R.; Engelbrecht, B.; Schiffer, M.; Kimura,  
37 K.; Freitag, P.; Carls, E.; Geisen, C.; Duerr, G. D.; Sasse, P.; Welz, A.; Pfeifer, A.; Salama,  
38 G.; Kotlikoff, M.; Fleischmann, B. K. Overexpression of Cx43 in Cells of the Myocardial  
39 Scar: Correction of Post-Infarct Arrhythmias Through Heterotypic Cell-Cell Coupling. *Sci.*  
40 *Rep.* **2018**, *8*(1), 7145-7145.
- 41 [91] Clausen, M. V.; Hilbers, F.; Poulsen, H. The Structure and Function of the Na,K-ATPase  
42 Isoforms in Health and Disease. *Front. Physiol.* **2017**, *8*(371),.

- 1 [92] Schwinger, R. H. G.; Bundgaard, H.; Müller-Ehmsen, J.; Kjeldsen, K. The Na, K-ATPase in  
2 the Failing Human Heart. *Cardiovas. Res.* **2003**, *57*(4), 913-920.
- 3 [93] Padma, V. V.; Poornima, P.; Prakash, C.; Bhavani, R. Oral Treatment with Gallic Acid and  
4 Quercetin Alleviates Lindane-Induced Cardiotoxicity in Rats. *Can. J. Physiol. Pharmacol.*  
5 **2012**, *91*(2), 134-140.
- 6 [94] Johnson, G. L.; Lapadat, R. Mitogen-Activated Protein Kinase Pathways Mediated by Erk,  
7 Jnk, and P38 Protein Kinases. *Science.* **2002**, *298*(5600), 1911-2.
- 8 [95] Vlahopoulos, S.; Zoumpourlis, V. C. JNK: A Key Modulator of Intracellular Signaling.  
9 *Biochem.* **2004**, *69*(8), 844-854.
- 10 [96] Yoon, Y. W.; Kang, T. S.; Lee, B. K.; Chang, W.; Hwang, K. C.; Rhee, J. H.; Min, P. K.;  
11 Hong, B. K.; Rim, S. J.; Kwon, H. M. Pathobiological Role of Advanced Glycation  
12 Endproducts via Mitogen-Activated Protein Kinase Dependent Pathway in the Diabetic  
13 Vasculopathy. *Exp.Mol. Med.* **2008**, *40*, 398.
- 14 [97] Fishman, S. L.; Sonmez, H.; Basman, C.; Singh, V.; Poretzky, L. The Role of Advanced  
15 Glycation End-Products in the Development of Coronary Artery Disease in Patients with  
16 and without Diabetes Mellitus: A Review. *Mol. Med.* **2018**, *24*(1), 59-59.
- 17 [98] Hu, P.; Lai, D.; Lu, P.; Gao, J.; He, H. ERK and Akt Signaling Pathways are Involved in  
18 Advanced Glycation End Product-Induced Autophagy in Rat Vascular Smooth Muscle  
19 Cells. *Int. J. Mol. Med.* **2012**, *29*(4), 613-8.
- 20 [99] Prasad, A.; Bekker, P.; Tsimikas, S. Advanced Glycation End Products and Diabetic  
21 Cardiovascular Disease. *Cardiol. Rev.* **2012**, *20*(4), 177-83.
- 22 [100] Eddy, A. A.; Neilson, E. G. Chronic Kidney Disease Progression. *J. Am. Socie. Nephrol.*  
23 **2006**, *17*(11), 2964-2966.
- 24 [101] Ryu, Y.; Jin, L.; Kee, H. J.; Piao, Z. H.; Cho, J. Y.; Kim, G. R.; Choi, S. Y.; Lin, M. Q.;  
25 Jeong, M. H. Gallic Acid Prevents Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis  
26 Through Regulation Of JNK2 Signaling and Smad3 Binding Activity. *Sci. Rep.* **2016**, *6*,  
27 34790.
- 28 [102] Jin, L.; Lin, M. Q.; Piao, Z. H.; Cho, Kim, G. R.; Choi, S. Y.; Ryu, Y.; Sun, S.; Kee, H. J.;  
29 Jeong, M. H. Gallic Acid Attenuates Hypertension, Cardiac Remodeling, and Fibrosis in  
30 Mice with NGG-Nitro-L-Arginine Methyl Ester-Induced Hypertension via Regulation of  
31 Histone Deacetylase 1 Or Histone Deacetylase 2. *J. Hypertens.* **2017**, *35*(7), 1502-1512.
- 32 [103] Jin, L.; Piao, Z. H.; Sun, S.; Liu, B.; Kim, G. R.; Seok, Y. M.; Lin, M. Q.; Ryu, Y.; Choi,  
33 S. Y.; Kee, H. J. Gallic Acid Reduces Blood Pressure and Attenuates Oxidative Stress and  
34 Cardiac Hypertrophy in Spontaneously Hypertensive Rats. *Sci. Rep.* **2017**, *7*(1), 15607.
- 35 [104] Umadevi, S.; Gopi, V.; Simna, S.; Parthasarathy, A.; Yousuf, S.; Elangovan, V. Studies on  
36 the Cardio Protective Role of Gallic Acid Against Age-Induced Cell Proliferation and  
37 Oxidative Stress in H9C2 (2-1) Cells. *Cardiovas. Toxicol.* **2012**, *12*(4), 304-311.
- 38 [105] Umadevi, S.; Gopi, V.; Vellaichamy, E. Inhibitory Effect of Gallic Acid on Advanced  
39 Glycation End Products Induced Up-Regulation of Inflammatory Cytokines and Matrix  
40 Proteins In H9C2 (2-1) Cells. *Cardiovas. Toxicol.* **2013**, *13*(4), 396-405.



- 1 [106] Sevgi, K.; Tepe, B.; Sarikurkcü, C. Antioxidant and DNA Damage Protection Potentials  
2 of Selected Phenolic Acids. *Food Chem. Toxicol.* **2015**, *77*, 12-21.
- 3 [107] Chamorro, S.; Viveros, A.; Alvarez, I.; Vega, E.; Brenes, A. Changes in Polyphenol and  
4 Polysaccharide Content of Grape Seed Extract and Grape Pomace After Enzymatic  
5 Treatment. *Food Chem.* **2012**, *133*(2), 308-314.
- 6 [108] Dianat, M.; Sadeghi, N.; Badavi, M.; Panahi, M.; Moghadam, M. T. Protective Effects of  
7 Co-Administration of Gallic Acid and Cyclosporine on Rat Myocardial Morphology Against  
8 Ischemia/Reperfusion. *Jundishapur J. Nat. Pharma. Prod.* **2014**, *9*(4).
- 9 [109] Rehman, M. U.; Tahir, M.; Ali, F.; Qamar, W.; Lateef, A.; Khan, R.; Quaiyoom, A.;  
10 Sultana, S. Cyclophosphamide-Induced Nephrotoxicity, Genotoxicity, and Damage in  
11 Kidney Genomic Dna of Swiss Albino Mice: The Protective Effect of Ellagic Acid. *Mol.*  
12 *Cell. Biochem.* **2012**, *365*(1-2), 119-127.
- 13 [110] Singh, J. P.; Singh, A. P.; Bhatti, R. Explicit Role of Peroxisome Proliferator-Activated  
14 Receptor Gamma in Gallic Acid-Mediated Protection Against Ischemia-Reperfusion-  
15 Induced Acute Kidney Injury in Rats. *J. Surg. Res.* **2014**, *187*(2), 631-639.
- 16 [111] Palipoch, S. A Review of Oxidative Stress in Acute Kidney Injury: Protective Role of  
17 Medicinal Plants-Derived Antioxidants. *African J. Trad. Complement. Alter. Med.* **2013**,  
18 *10*(4), 88-93.
- 19 [112] Kim, D. O.; Lee, K. W.; Lee, H. J.; Lee, C. Y. Vitamin C Equivalent Antioxidant Capacity  
20 (VCEAC) of Phenolic Phytochemicals. *J. Agri. Food Chem.* **2002**, *50*(13), 3713-3717.
- 21 [113] Kahkeshani, N.; Farzaei, F.; Fotouhi, M.; Alavi, S. S.; Bahramsoltani, R.; Naseri, R.;  
22 Momtaz, S.; Abbasabadi, Z.; Rahimi, R.; Farzaei, M. H.; Bishayee, A. Pharmacological  
23 Effects of Gallic Acid in Health and Disease: A Mechanistic Review. *Iranian J. Basic Med.*  
24 *Sci.* **2019**, *22*(3) (2019) 225-237.

25  
26  
27  
28  
29  
30  
31  
32  
33  
34

1 **Table 1:** Chemical name, molecular formula, chemical group and reported pharmacological  
 2 activity of GA

| IUPAC Name                   | Molecular formula                                    | Chemical Group | Reported Pharmacological activity  | References                    |
|------------------------------|--|----------------|--|-------------------------------|
| 3,4,5-trihydroxybenzoic acid | C <sub>6</sub> H <sub>2</sub> (OH) <sub>3</sub> COOH | Polyphenol     | Antioxidant<br>Anti-inflammatory<br>Anti-diabetic<br>Anti-mutagenic<br>Cardioprotective<br>Hepatoprotective<br>Nephroprotective<br>Anti-cancer<br>Gastroprotective | [12, 30, 34, 75, 89, 106-113] |

3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

1 **Table 2:** *In vivo* anti-diabetic activity of GA with its test model, dose used, route of  
 2 administration and possible mechanism of action.

| Test model   | Dose/b.w                        | Route of administration | Mechanism of action  | Reference |
|--|---------------------------------|-------------------------|--|-----------|
| STZ-induced diabetic rat                             | 20 mg/kg for 28 days            | Orally                  | Reduction of serum TC, TG, LDL-C, urea, UA, creatinine and increased plasma insulin, C-peptide and glucose tolerance level.  | [30]      |
| STZ-induced diabetic rat                             | 10 and 20 for 21 days           | Orally                  | Reduction of blood glucose and increased plasma insulin.   | [31]      |
| Alloxan-induced diabetic female rabbit               | 100 mg/kg for 21 days           | Intravenously           | Reduction of blood glucose and serum MDA levels.   | [34]      |
| STZ-induced oxidative stress in diabetic rat         | 25 mg/kg for 35 days            | Orally                  | Significant increase of pancreatic vitamin C and glutathione level and improved ROS scavenging, Fe <sup>2+</sup> chelation and Fe <sup>3+</sup> reduction property of the pancreas | [32]      |
| Alloxan-induced oxidative stress in diabetic rat     | 5, 10, and 20 mg/kg for 45 days | Orally                  | Reduction of blood glucose, increase insulin level, and upregulation of antioxidant enzymes (CAT, SOD, and GPx)  | [33]      |
| High fat diet-induced obesity mice                   | 10 mg/kg for 14 days            | Intraperitoneally       | Reduction of blood glucose, TG, adipocyte size and upregulation of PPAR $\gamma$ expression and activation of Akt signaling pathway  | [54]      |
| High-fat diet fed-STZ-induced insulin resistance rat | 20 mg/kg for 30 days            | Orally                  | Enhancing glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway   | [53]      |
| STZ-induced diabetic rat                             | 20 mg/kg for 42 days            | Orally                  | Reduction of TNF- $\alpha$ level and enhance upregulation of PPAR $\gamma$ mRNA and adiponectin  | [55]      |
| High fat diet-induced obesity mice                   | 10 mg/kg for 28 days            | Intraperitoneally       | Activation of AMPK and regulates mitochondrial function via the activation of PGC1 $\alpha$  | [56]      |

3

4

1 **Table 3:** *In vivo* cardioprotective activity of GA with its test model, dose used, route of  
 2 administration and possible mechanism of action

| Test model  | Dose/b.w                          | Route of administration | Mechanism of action   | Reference |
|---|-----------------------------------|-------------------------|---|-----------|
| ISO-induced myocardial infarction in male Wistar rats | 15 mg/kg for 10 days              | Orally                  | Reduction of LPO and myocardial infarction biomarker (↓CK, CK-MB, AST, alanine transaminase (ALT), LDH and troponin-T) as well as upregulation of enzymatic (↑SOD, CAT, GPx, GR and GST) and non-enzymic antioxidants (↑GSH, vitamin C and E) in plasma and heart   | [75]      |
| STZ-induced diabetic rat                              | 100, 50, and 25 mg/kg for 8 weeks | Orally                  | Reduction of serum glucose and LPO (↓TG, TC, LDL-C, VLDL-C) as well as increased dose dependently antioxidant parameters in heart   | [76]      |
| DOX- induced cardiotoxicity in rat                    | 15 mg and 30 mg/kg                | Orally                  | Reduction of LPO (↓CK-MB, MDA, TG, TC, LDL in serum) as well as increased non-enzymic antioxidant (GSH) and antioxidant enzymes (↑CAT and SOD) in the heart   | [77]      |
| Alumina -induced myocardial injury in rat             | 100 mg/kg for 14 days             | Orally                  | Reduction of LPO (↓CPK, CK-MB, TG, TC, LDL and LDH in serum) and increased antioxidant enzymes (↑GR, CAT and SOD) as well as upregulation of gap junction protein connexin 43 (Cx43) in heart   | [78]      |
| ISO- treated myocardial infarcted rats                | 15 mg/kg for 10 days              | Orally                  | Reduction of LPO (↓CK-MB, LDH, thiobarbituric acid reactive substances (TBARS), lipid hydroperoxides (LOOH)) and reduction of activity of lysosomal enzymes (↓β-glucuronidase, β-N-acetylglucosaminidase, β-galactosidase, cathepsin-B and D) as well as increased non-enzymic antioxidant (GSH) in the serum and heart of myocardial infarcted rat | [89]      |
| Lindane- induced cardiotoxicity in rat                | 15 mg/kg for 30                   | Orally                  | Reduction of serum cardiac marker enzymes, LPO, and membrane-bound Ca <sup>2+</sup> ATPase, with a concomitant increased of non-enzymic antioxidant   | [93]      |

|   |                                    |                   |  |       |
|---|------------------------------------|-------------------|--|-------|
|   | days                               |                   | (GSH) and enzymic antioxidants ( $\uparrow$ SOD, CAT, GPx, and GST) as well as membrane-bound $\text{Na}^+/\text{K}^+$ ATPase in heart tissue  |       |
| Ischemia reperfusion in isolated rat heart tissue                   | 7.5,15,30 mg/kg for 10 days        | Orally            | Reduction of LPO ( $\downarrow$ MDA, LDH)and increased antioxidant enzymes ( $\uparrow$ CAT, SOD, GPx) in heart tissue.  | [87]  |
| Ischemia reperfusion in isolated rat hearts with alloxan-induced DM | 25mg/kg for 8 weeks                | Orally            | Reduction of LPO ( $\downarrow$ CK-MB, troponin I, LDH)and increased antioxidant enzymes ( $\uparrow$ CAT, SOD, GPx) in diabetic heart tissue. It also improved both left ventricular dysfunction and hypertrophy through antioxidant mechanism  | [86]  |
| AGEs- induced oxidative stress rat                                  | 25 mg/kg for 30 days               | Orally            | Reduction of LPO ( $\downarrow$ CK, LDH) and protein carbonyls (PCO)in plasmaand increased non-enzymic antioxidant (GSH) and enzymatic antioxidants ( $\uparrow$ SOD, CAT) in heart tissue   | [79]  |
| ISO-induced cardiac hypertrophy in mice                             | 100 mg/kg for 3 weeks              | Intraperitoneally | Downregulation of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and beta-myosin heavy chain (MHC- $\beta$ ) as well as prevention of interstitial collagen deposition and expression of fibrosis-associated genes in cardiac tissues. Overall, prevention of cardiac hypertrophy and fibrosis through regulating the JNK2 and Smad3 signaling pathway | [101] |
| CoCl <sub>2</sub> -induced cardiorenal damage in rats               | 120 mg/kg for 14 days              | Orally            | Reduction of oxidative stress ( $\downarrow$ serum CK-MB, LDH, AST, xanthine oxidase (XO), urea, MDA, creatinine, H <sub>2</sub> O <sub>2</sub> , NO, and $\uparrow$ SOD, CAT, GST) and activation of ERK  | [80]  |
| Diazinon-induced cardiovascular dysfunction in rat                  | 60 mg/kg and 120 mg/kg for 21 days | Orally            | Reverses the oxidative stress markers ( $\downarrow$ MDA, H <sub>2</sub> O <sub>2</sub> , NO, and $\uparrow$ GSH, SOD, CAT, GST) and increased antioxidant defense system as well as and reduces deleterious effects on hematological parameters   | [85]  |
| NaF-induced oxidative stress in rat's heart                         | 10 and 20 mg/kg for 7 days         | Intraperitoneally | Reduction of LPO ( $\downarrow$ TBARS, MDA) and increased non-enzymic antioxidant (GSH) and enzymatic antioxidants ( $\uparrow$ SOD,   | [81]  |

|  |                                   |                   |  |       |
|--|-----------------------------------|-------------------|--|-------|
|  |                                   |                   | CAT) activity in heart tissue  |       |
| Isoprenaline-induced myocardium infraction in rats | 15 mg/kg for 10 days              | Orally            | Reduction of cardiac marker enzymes activity (AST, ALT, CK and LDH), LPO (MDA) and elevated antioxidant parameters (↓SOD, GSH)   | [83]  |
| CYP-induced cardiorenal dysfunction in rat         | 60 and 120 mg/kg for 7 days       | Intraperitoneally | Reduction of LPO (↓MDA, H <sub>2</sub> O <sub>2</sub> ) and restores the enzymic (↑SOD, GPx, CAT, GST) and non-enzymic (↑GSH) antioxidants and also attenuates cardiotoxicity through free radical scavenging activity | [82]  |
| DOX- induced cardiac dysfunction in rat            | 60 and 120 mg/kg for 7 days       | Orally            | Improving antioxidant defense system (↑CAT, GST, GPx and GSH) and reduction of cardiac tissue LPO (↓MDA, LDH, CK-MB)   | [84]  |
| L-NAME-induced hypertensive mice                   | 50 and 100 mg/kg during 3-6 weeks | Intraperitoneally | Reduces left ventricular (LV) posterior wall thickness and interventricular septum thickness. Anti-fibrosis effect through downregulation of ECM proteins (collagen type I, collagen type III, and CTGF)               | [102] |
| Spontaneously hypertensive rats (SHRs) rat         | 320 mg/rat for 16 weeks           | Orally            | Reduced BP through components of the renin-angiotensin II system as well as reduction of cardiac hypertrophy via down regulation of cardiac-specific GATA4-induced Nox2  | [103] |

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8

1 **Table 4:** *In vitro* cardioprotective activity of GA with test model, concentration used, proposed  
 2 mechanism of action


| Reported activity | Test model   | Concentration  | Mechanism  | Reference |
|-------------------|--|----------------|--|-----------|
| Anti-diabetic     | Cultured 3T3-L1 cells  | 10 $\mu$ M     | Stimulation of glucose uptake through translocation and activation of GLUT4 in Akt signaling pathway   | [57]      |
|                   | Cultured rat pancreas homogenates                            | 20 $\mu$ M     | Reduction of MDA contents, improved ROS scavenging, Fe <sup>2+</sup> chelation and Fe <sup>3+</sup> reduction property of the cultured cells and inhibition of $\alpha$ -amylase and $\alpha$ -glucosidase | [35]      |
|                   | Cultured RINm5F $\beta$ -cell                                | 0.3–10 $\mu$ M | Significant increase insulin secretion and upregulation of mRNA of PDX-1 in cultured cells   | [58]      |
|                   | <i>In vitro</i> insulin fibril formation                     | 0-17 mM        | Prevention of insulin amyloid fibril formation.  | [59]      |
| Cardioprotective  | AGE-induced oxidative stressed in cultured (H9c2(2-1)) cells | 10 $\mu$ M     | Elevation of antioxidant defense mechanism (SOD, CAT, GSH) and scavenging ROS as well as reduction of LPO  | [104]     |
|                   | AGE-treated in cultured H9c2(2-1) cell                       | 10 $\mu$ M     | Attenuates upregulation of AGE-induced cytokines (TNF- $\alpha$ , TGF- $\beta$ , iNOS and matrix proteins, RAGE, TIMPs, MMP)   | [105]     |
|                   | L-NAME treated cultured H9c2(2-1) cells                      | 100 $\mu$ M    | Attenuation of cardiac fibrosis and reduced the expression of histone deacetylase 1 and 2  | [102]     |
|                   | ISO treated cultured H9c2(2-1) cells                         | 100 $\mu$ M    | Downregulation of ANP, BNP, and MHC- $\beta$ as well as downregulation of JNK2 and Smad3 signaling pathway   | [101]     |
|                   | Renin-angiotensin II treated cultured H9c2(2-1) cell         | 100 $\mu$ M    | Downregulation of GATA4-induced Nox activity in angiotensin II-treated H9c2(2-1) cells   | [103]     |

3

4

1

2



3

4

**Figure 1.** Structure of Gallic acid and its derivatives

5

6

7

8

9


10

11

12

13





12 **Figure 2.** Workflow of database searches with literature inclusion and exclusion criteria.


13

14

15

16

17



1

2

3

**Figure 3.** Proposed anti-diabetic and cardioprotective mechanism of action of GA